January 31, 2002
AmeriPath to Present at Healthcare Conference

FOR IMMEDIATE RELEASE

Contact: Gregory A. Marsh Vice President & CFO AmeriPath, Inc. 561-712-6211

Michelle D. Getty Investor Relations AmeriPath, Inc. 561-712-6260 E-mail: invrel@ameripath.com

AMERIPATH, INC. TO PRESENT AT U.S. BANCORP PIPER JAFFRAY HEALTHCARE CONFERENCE

Riviera Beach, FL, January 30, 2002 – AmeriPath, Inc. (Nasdaq:PATH), one of the nation’s leading providers of anatomic pathology services, today announced it will participate in the U.S. Bancorp Piper Jaffray Healthcare Conference to be held at the The Pierre Hotel in New York City, New York. The AmeriPath presentation will be made by the Company’s Vice President and Chief Financial Officer, Gregory A. Marsh along with Dennis M. Smith, Jr., M.D., Executive Vice President of Genomic Strategies and Chief Medical Officer on Thursday, January 31, 2002, at 2:00 p.m. Eastern Time.

The public is invited to listen to a webcast of the live presentation via the Internet and an archived replay for 60 days at the following web addresses: Using Real Media: http://www.on24.com/clients/piperjaffray/conference_020129/index.html?presenter=ameripath&format=rmmulti. Using Windows Media: http://www.on24.com/clients/piperjaffray/conference_020129/index.html?presenter=ameripath&format=wmmulti. The webcast and replay will also be available on the Investor Relations page of the AmeriPath website, http://www.ameripath.com/.

AmeriPath is a leading national provider of cancer diagnostics, genomics, and related information services. During the first nine months of 2001, AmeriPath diagnosed approximately 2.9 million tissue biopsies, and interpreted approximately 1.6 million Pap smears. The company’s extensive diagnostics infrastructure includes over 400 pathologists and doctorate-level scientists providing services in 42 independent pathology laboratories, more than 200 hospitals, the Center for Advanced Diagnostics (CAD) and Dermpath Diagnostics. CAD provides specialized diagnostic testing and information services including Fluorescence In-Situ Hybridization (FISH), Flow Cytometry, DNA Analysis, Polymerase Chain Reaction (PCR), Molecular Genetics, Cytogenetics and HPV Typing. AmeriPath has over 60 board-certified dermatopathologists supporting Dermpath Diagnostics, one of the country’s leading providers of dermatopathology services in the growing skin diagnostic market. Additionally, AmeriPath provides clinical trial and research development support to firms involved in developing new cancer and genomic diagnostics and therapeutics.